[144] Surgery Partners, Inc. SEC Filing

Rhea-AI Filing Summary

Surgery Partners, Inc. (SGRY) Form 144: This notice reports a proposed sale of 9,339 shares of common stock to be executed through UBS Financial Services Inc. on or about 09/04/2025 with an aggregate market value of $209,944. The shares were acquired on 09/01/2025 through equity vesting as equity compensation from Surgery Partners, Inc.

The filing lists 128,209,410 shares outstanding for the issuer. Several standard filer and issuer identification fields (including the name of the person for whose account the securities are to be sold and filer CIK/CCC) are not populated in the provided content.

Positive

• Transaction disclosed under Rule 144, providing regulatory transparency
• Securities were acquired as equity compensation, and the filing states the acquisition and planned sale dates

Negative

• Name of the person for whose account the securities are to be sold is not provided in the supplied content
• Filer identification fields (CIK/CCC and contact details) are not populated in the provided content

Insights

Securities Analyst

TL;DR: Insider plans to sell newly vested equity through UBS for about $210k; filing lacks identifying filer details.

The Form 144 shows a planned sale of 9,339 common shares acquired via equity vesting three days earlier and designated as equity compensation. The execution is routed through UBS Financial Services with an approximate sale date of 09/04/2025. The disclosure includes the issuer's outstanding share count (128,209,410) and the aggregate market value reported. The filing does not supply the seller's name or filer identifiers in the provided content, which limits assessment of insider status or potential tax/trading-plan context.

Corporate Governance Expert

TL;DR: Routine Rule 144 notice for vested equity; absence of identifying details reduces transparency for stakeholders.

The document documents a Rule 144 notification for securities obtained by equity vesting and intended for sale through a broker. It affirms the seller's representation about lack of undisclosed material adverse information. However, key issuer/filer identity fields are blank in the provided content, constraining verification of insider relationships, potential blackout periods, or whether sales align with a pre-existing trading plan.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	9339	209944	128209410	09/04/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
common	09/01/2025	Equity Vesting	Surgery Partners, Inc.			9339	09/01/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Surgery Partners (SGRY) report?

The filing reports a proposed sale of 9,339 common shares through UBS Financial Services with aggregate market value $209,944 and an approximate sale date of 09/04/2025.

How were the shares acquired that are being sold?

The shares were acquired on 09/01/2025 by equity vesting from Surgery Partners, Inc., classified as equity compensation.

Does the filing identify the seller or filer details?

In the provided content, the name of the person for whose account the securities are to be sold and filer identifiers (CIK/CCC) are not filled in.

What broker will execute the sale?

The broker named in the filing is UBS Financial Services Inc., 1000 Harbor Blvd, Weehawken, NJ.

How many shares outstanding does the filing list for the issuer?

The filing lists 128,209,410 shares outstanding for the issuer.